A growing body of evidence suggests that epigenetic agents can heighten tumor immunogenicity by up-regulating the expression of tumor antigens, MHC molecules, and other molecules involved in antigen processing and presentation [109–111], sensitize tumor cells to NK group 2 member D (NKG2D)-mediated cytotoxicity of NK and T cells by inducing expression of MHC class I–related chain A and B (MICA/B) [112, 113], and reduce Treg cells and MDSCs [114, 115]. This evidence concerns the gene HLA-C and neoplasm.